Scarica l'app Stockscreener
0.7778
3.02%
0.0228
Dopo l'orario di chiusura:
.77
-0.0078
-1.00%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.755
Aprire:
$0.77
Volume 24 ore:
285.03K
Relative Volume:
0.26
Capitalizzazione di mercato:
$13.65M
Reddito:
-
Utile/perdita netta:
$-16.60M
Rapporto P/E:
-0.8739
EPS:
-0.89
Flusso di cassa netto:
$-23.48M
1 W Prestazione:
-3.40%
1M Prestazione:
-73.27%
6M Prestazione:
-82.64%
1 anno Prestazione:
-91.81%
Intervallo 1D:
$0.755
$0.7832
Intervallo di 1 settimana:
$0.71
$0.8148
Portata 52W:
$0.69
$29.40
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Nome
Briacell Therapeutics Corp
Settore
Industria
Telefono
(604) 921-1810
Indirizzo
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Confronta BCTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCTX
Briacell Therapeutics Corp
|
0.7778 | 13.25M | 0 | -16.60M | -23.48M | -0.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.98 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.90 | 60.58B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
418.91 | 54.99B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
674.90 | 42.25B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.23 | 32.93B | 3.81B | -644.79M | -669.77M | -6.24 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-02-14 | Iniziato | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Borsa (BCTX) Ultime notizie
BriaCell Announces Share Consolidation to Maintain Nasdaq Compliance - TipRanks
BriaCell Sets August 25 for Major 10:1 Share Consolidation: What Shareholders Must Know - Stock Titan
BriaCell Announces Proposed Effective Date of Share Consolidation - GlobeNewswire
Simon Property Reports Strong Q2 2025 Financial Results - The Globe and Mail
What institutional investors are buying BriaCell Therapeutics Corp. Equity Warrant stockUnlock powerful stock screening techniques - Jammu Links News
How does BriaCell Therapeutics Corp. compare to its industry peersDiscover high-impact investment opportunities - Jammu Links News
How does BriaCell Therapeutics Corp. Equity Warrant generate profit in a changing economySuperior risk-adjusted returns - Jammu Links News
(BCT) Technical Pivots with Risk Controls (BCT:CA) - news.stocktradersdaily.com
What institutional investors are buying BriaCell Therapeutics Corp. stockDiscover the next big stock winners - Jammu Links News
What makes BriaCell Therapeutics Corp. stock price move sharplyCapitalize on emerging trends for profits - Jammu Links News
How volatile is BriaCell Therapeutics Corp. Equity Warrant stock compared to the marketMassive portfolio appreciation - Jammu Links News
BriaCell Therapeutics Corp. Equity Warrant Stock Analysis and ForecastGet daily updates on promising stocks - Jammu Links News
How does BriaCell Therapeutics Corp. Equity Warrant compare to its industry peersHigh-octane gains - Jammu Links News
What makes BriaCell Therapeutics Corp. Equity Warrant stock price move sharplyUnlock powerful market insights for success - Jammu Links News
What drives BriaCell Therapeutics Corp. Equity Warrant stock priceMaximize returns with data-driven strategies - Jammu Links News
What is the dividend policy of BriaCell Therapeutics Corp. Equity Warrant stockMaximize gains with expert analysis - Jammu Links News
Published on: 2025-08-03 12:02:14 - Jammu Links News
What is the risk reward ratio of investing in BriaCell Therapeutics Corp. Equity Warrant stockAchieve consistent double-digit returns - Jammu Links News
Should I hold or sell BriaCell Therapeutics Corp. Equity Warrant stock in 2025Tremendous return rates - Jammu Links News
What catalysts could drive BriaCell Therapeutics Corp. Equity Warrant stock higher in 2025Invest smarter with comprehensive market analysis - Jammu Links News
How does BriaCell Therapeutics Corp. generate profit in a changing economyProven strategies for superior portfolio growth - Jammu Links News
What catalysts could drive BriaCell Therapeutics Corp. stock higher in 2025Sky-high return potential - Jammu Links News
Is BriaCell Therapeutics Corp. Equity Warrant stock overvalued or undervaluedRapid portfolio appreciation - Jammu Links News
Is it the right time to buy BriaCell Therapeutics Corp. Equity Warrant stockDouble-digit growth - Jammu Links News
Off-market insider buying at Atico Mining (ATY) - The Globe and Mail
BriaCell Therapeutics Corp. Recovery Hinges on Volume BreakoutWeekly Setup With 3x Return Potential Published - metal.it
Is BriaCell Therapeutics Corp. a growth stock or a value stockPre Market Review For Consistent Profits - Jammu Links News
BriaCell Expands Phase 3 Breast Cancer Study with UCLA Health Partnership - TipRanks
UCLA Health joins BriaCell’s phase 3 breast cancer study By Investing.com - Investing.com Nigeria
UCLA Health joins BriaCell’s phase 3 breast cancer study - Investing.com
BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study - GlobeNewswire
FDA Fast-Tracked: UCLA Health to Test BriaCell's Novel Breast Cancer Immunotherapy in Pivotal Phase 3 Trial - Stock Titan
Foraco International reports Q2 2025 - The Globe and Mail
WALSH PURE SPREADER -Pure Hedge Division - The Globe and Mail
BriaCell granted New Zealand patent for cancer immunotherapy method By Investing.com - Investing.com South Africa
BriaCell granted New Zealand patent for cancer immunotherapy method - Investing.com
BriaCell Awarded New Zealand Patent for its Whole Cell Technology - GlobeNewswire
Why BriaCell Therapeutics Corp. Equity Warrant stock attracts strong analyst attentionInvestment Playbook for Growing Markets Shared - metal.it
BriaCell Secures New Zealand Patent for Cancer Immunotherapy - TipRanks
BriaCell Secures Game-Changing Cancer Immunotherapy Patent: Breakthrough in Personalized Treatment - Stock Titan
Published on: 2025-07-30 10:30:41 - metal.it
BriaCell Therapeutics Files Patent for Cancer Treatment Platform - AInvest
Is BriaCell Therapeutics Corp. Equity Warrant a Top Dividend Stock to Watch in 2025 - metal.it
BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents - GlobeNewswire
BriaCell Therapeutics Corp. Recovery Linked to Earnings SurpriseDaily Momentum Screener With Alerts Launched - metal.it
Published on: 2025-07-29 17:12:14 - metal.it
BriaCell Therapeutics Corp. Equity Warrant Recovers — But Is It SustainableReal Time Trade Opportunity Alerts Monitor Market Surges - metal.it
BriaCell’s BriaPro Files Patent for Innovative Cancer Treatment Platform - TipRanks
Revolutionary Cancer Treatment: BriaCell's New Platform Targets 5 Major Cancer Types Simultaneously - Stock Titan
Why did BCTX report zero EPS for Q3 2023? - AInvest
Published on: 2025-07-29 07:17:26 - metal.it
Briacell Therapeutics Corp Azioni (BCTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.40%
0.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):